CubiCasa Enters Australian and New Zealand Real Estate Market Through Partnership with Bladescenes

CubiCasa, a global-reaching real estate software company headquartered in Oulu, Finland, has announced a partnership with Bladescenes, a leading creative marketing agency for real estate located in Auckland, New Zealand. This partnership marks a notable boost to CubiCasa’s ongoing expansion into the Australian and New Zealand real estate markets, accelerating the global growth of its mobile property scanning technology.

Bladescenes offers creative photography, videography, and now virtual floor plans as a part of its agency services. Bladescenes markets homes by capturing their prepossessing architect and layout potential through the use of digital technology. CubiCasa’s mobile capture technology gives Bladescenes’ customers the capability to visualize their dream floor plan while speeding up the home inspection and valuation process.

“By partnering with Bladescenes, we are continuing to work toward our mission of modernizing and digitizing the real estate process on a global scale,” said Jeff Allen, President of CubiCasa. “This relationship gives us the opportunity to become the one-stop shop for real estate and mortgage professionals in Australia and New Zealand while continuing to expand in the U.S., Europe, and other target markets.”

CubiCasa, which was founded in 2014 and launched its scanning solution in 2019, has successfully entered the Australian and New Zealand markets, furthering its growth by partnering with successful players in the real estate industry. The company is working with close to 40 leading companies across both countries.

“CubiCasa’s technology will allow us to integrate floor plan and sketch capabilities into our offering along with photography,” said George McNabb, Creative Director of Bladescenes. “By using CubiCasa’s easy-to-use app, we are seeing increased adoption and lower margin of error. CubiCasa has totally changed our business and we are grateful to be partnering with them.”

About CubiCasa

Headquartered in Oulu, Finland, CubiCasa is the global market leader in mobile indoor scanning and is known for its fast and easy-to-use floor plan app on the App Store and Google Play Store. CubiCasa’s technology is used in 144 different countries and has helped create over 1 million floor plans to date. CubiCasa provides technology for the real estate, appraisal, and mortgage industries and is on a mission to digitize real estate. http://www.cubi.casa/

About Bladescenes

Founded in 2012, Bladescenes remains at the forefront of real estate technology and marketing, offering a range of services that includes photography, videography, floor planning, virtual open homes, and virtual staging. With our dedicated team of real estate experts and advanced technology, Bladescenes ensures agents and homeowners have access to the leading and most creative ways to list and sell a property. https://www.bladescenes.com/

CubiCasa Media Contact
Ross Stevens
Caliber Corporate Advisers for CubiCasa
803-549-7529
ross@calibercorporate.com

Padini Enters Partnership with XTS and Huawei Malaysia for RM1 Million Investment in Warehouse Automation Solution

XTS Technologies Sdn. Bhd. (XTS), a leading specialist in the design and build of factory automation solutions, and Huawei Technologies (M) Sdn. Bhd. (Huawei), a leading global provider of information and communications technology (ICT) infrastructure and smart devices, has signed a Memorandum of Understanding (MoU) with Padini Dot Com Sdn. Bhd., a subsidiary of Padini Holdings Berhad (Padini, Bursa: Main, 7052) for a warehouse automation solution using automated guided vehicles (AGVs) valued at RM1 million to be delivered within one year of a confirmed order.

Top 1st row, R: Mr. Lim Chee Siong, Huawei Malaysia’s VP of the Cloud and AI Business; 2nd row, L: Mr. Xteven Teoh, Managing Director of XTS and 3rd row, R: Mr. Andrew Yong, General Manager (Operations) of Padini, at the digital MoU signing ceremony.

Padini is a fashion retailer offering two multi-brand labels – Padini Concept Store with eight brands including Padini, Seed, Padini Authentics, PDI, P&Co, Miki, Vincci and Vincci Accessories, and Brands Outlet. Padini is a fashion retailer operating outlets stores in malls across Malaysia as well as Cambodia, Indonesia, Bahrain, Brunei, Myanmar, Oman, Qatar, Thailand and United Arab Emirates.

The warehouse automation solution enables Padini to use AGVs of the reach truck type to assist in warehouse inbound and outbound picking of goods from the current manual system in which the reach truck driver needs to search for the required products on pallets from numerous racks in different locations in the warehouse.

With AGV reach trucks, data stored within the Huawei cloud storage system enables the automated reach trucks to accurately pinpoint where the goods are for picking, with the reach trucks able to navigate its way automatically in the warehouse.

Managing Director of XTS, Xteven Teoh said, “We are proposing through this MoU to design and build the warehouse automation solution using AGVs that can assist and streamline Padini in its warehouse operations. This is also our first warehouse automation solution project utilising AGVs.”

“The AGVs will replace Padini’s two manual reach trucks and two drivers per floor in its warehouse operations. The AGVs will mitigate the risks of human error as time is saved from having to search for the required pallets and there is less risk of goods and other properties being damaged. It is overall more efficient and with consistent outcomes.”

General Manager (Operation) of Padini, Andrew Yong, said, “The collaboration of this project with Huawei and XTS will certainly be a push to modernize the operations of the warehouse in relations to our push for IR 4.0 adoption in Padini. The scope of this project is a small portion of the operations with minimum units to be deployed in the warehouse. During this trial phase, we hope to achieve a better productivity, efficiency and safety. We hope that this trial will be able to prove better consistency in our warehouse throughput, saving time and maintaining or improving the throughput of our operations and the working environment in our warehouse. We will be looking forward to this collaboration.”

Huawei Malaysia’s Vice President of the Cloud and AI Business, Mr. Lim Chee Siong said, “It is always our goal at Huawei Cloud to dive into digitalisation and to provide Everything as a Service (XaaS). We will continue to innovate with local partners to offer cutting-edge technologies to support customer’s digital transformation journey. We are proud to be chosen as the preferred cloud partner by XTS and serving Padini, this collaboration is just the beginning, and we will see more opportunities in future.”

XTS Technologies: https://www.xtstech.com/
Padini Dot Com: https://www.padini.com/
Huawei: https://www.huawei.com/en/






Topic: Press release summary

Japan – Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights for global research, development, manufacture and sale of the investigational anticancer agent H3B-8800 to a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV). H3B-8800 (Roivant’s Development Code: RVT-2001) is a splicing modulator compound, discovered by Eisai’s U.S. research subsidiary H3 Biomedicine Inc., which is undergoing development as an investigational anticancer agent.

H3B-8800 is an orally available small molecule modulator of splicing factor 3B subunit 1 (SF3B1), discovered by H3 Biomedicine Inc. Splicing occurs to remove introns that are base sequence of pre-messenger RNA (mRNA), unneeded for protein synthesis, in the process of synthesizing proteins based on the genetic code. Mutations in splicing factor-encoding genes are observed in multiple hematological malignancies and solid tumors. SF3B1 is a particularly frequent gene mutation in splicing factors.(1),(2) H3B-8800 binds to SF3B1, and demonstrated significant antitumor activity in preclinical models by modulating the disruption of mRNA splicing in cancer.(3) Eisai and H3 Biomedicine Inc. are currently conducting a Phase I clinical trial of H3B-8800 in the U.S. and Europe in patients with myelodysplastic syndrome carrying SF3B1 mutations.

Under the terms of the agreement, Eisai will receive a contractual up-front payment, development, and regulatory milestone payments for H3B-8800, and will also receive a certain amount of royalties on sales revenue of H3B-8800 after the launch.

Roivant is a biopharmaceutical company with a unique business model. Roivant builds and launches subsidiaries, called “Vants” which conduct efficient clinical development in diverse therapeutic areas. Eisai believes that this License Agreement with Roivant will lead to the maximization of the value of H3B-8800. Eisai will continue to accelerate its discovery of new medicines based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

About H3 Biomedicine, Inc.

H3 Biomedicine, Inc., a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments using its integrated data science, human biology and precision chemistry discovery engine with the goal of improving the lives of patients. The company was established on December 2010 as a subsidiary of Eisai’s U.S. pharmaceutical operation, Eisai Inc. H3 Biomedicine focuses on sustained long-term delivery of its pipeline, collaborating with Eisai Co., Ltd., who provides essential research funding and access to the capabilities and resources of a global pharmaceutical company.
For more information, please visit www.h3biomedicine.com.

About Roivant

Roivant’s mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology companies.

For more information, please visit www.roivant.com.

(1) Yoshida, et al. (2011). Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478(7367): 64-69. doi: 10.1038/nature10496.
(2) Seiler, et al. (2018). Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Reports 23(1): 282-296.e4. doi: 10.1016/j.celrep.2018.01.088.
(3) Seiler, et al. (2018). H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nature Medicine 24(4): 497-504. doi: 10.1038/nm.4493.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Japan – Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia

Eisai Co., Ltd. today announced it has entered into an agreement with Gilead Sciences, Inc. for the commercialization and distribution of filgotinib (generic name, product name: Jyseleca), an oral, JAK1 preferential inhibitor for indications of rheumatoid arthritis (RA), ulcerative colitis, and Crohn’s disease in Asia (South Korea, Taiwan, Hong Kong and Singapore). In December 2019, Eisai signed a partnership agreement with Gilead Sciences K.K., a Japanese subsidiary of Gilead, for the distribution and co-promotion of filgotinib in Japan.

Under the terms of the new agreement, Eisai will obtain an exclusive marketing right for filgotinib in South Korea, Taiwan, Hong Kong and Singapore from Gilead. Gilead has received approval for the treatment of RA in Taiwan and has applied for approval of filgotinib for the treatment of RA in South Korea. Following approvals, Eisai will take over the manufacturing and marketing licenses for filgotinib from Gilead in South Korea and Taiwan. In Hong Kong and Singapore, Eisai will apply for approval for filgotinib. With this agreement, Eisai will pay Gilead a contractual up-front payment, as well as regulatory milestones and sales milestones.

Filgotinib is a once-daily, oral, JAK1 preferential inhibitor. In Japan, filgotinib has been approved for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have had an inadequate response to conventional therapies. In April 2021, Gilead Sciences K.K. applied for an additional indication of filgotinib as a treatment for patients with moderate to severe active ulcerative colitis.

Eisai will leverage its strong business foundation throughout Asia, provide new treatment options for patients with rheumatoid arthritis and inflammatory bowel disease, and contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients their families, and healthcare providers.

About filgotinib

Filgotinib is a once-daily, oral, JAK1 preferential inhibitor. In Japan, filgotinib has been approved for the treatment of RA (including prevention of structural joint damage) in patients who have had an inadequate response to conventional therapies. In April 2021, Gilead Sciences K.K. applied for an additional indication of filgotinib as a treatment for patients with moderate to severe active ulcerative colitis.

In addition, filgotinib has been approved in the European Union and Great Britain for the treatment of adults with moderate to severe active rheumatoid arthritis who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). Filgotinib has also been approved in the European Union for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Applications have been submitted to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with moderately to severely active ulcerative colitis and are currently under review.

About the market for biological products South Korea, Taiwan, Hong Kong and Singapore

The market of biological products in 2020 in South Korea, Taiwan, Hong Kong and Singapore is approximately US $ 400 million, accounting for approximately more than 80% of the total market for biological products in Asia (Hong Kong, India, Indonesia, South Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam).(1) Many of biological products are adapted in the treatments for rheumatoid arthritis and inflammatory bowel disease.

(1) Copyright 2021 IQVIA. Internal analysis based on IQVIA Analytics Link 2020. Unauthorized reproduction prohibited.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

SnapCheck Enters Into Definitive Agreement to be Acquired

 SnapCheck, the multi-award platform for business payments modernization, today announced that it has entered into a definitive agreement to be acquired. The buyer is an investment group aligned exclusively with Payroc World Access. By combining the transformative SnapCheck platform with Payroc’s recently acquired ACHeck21 Fintech Cloud solution, the buyer foresees the emergence of an entirely new dimension in payments.

SnapCheck is a high speed, highly secure, and universally accepted solution dedicated to eliminating paper checks. Created as an open-ecosystem platform for paying anyone anywhere with the familiar form of a check, but without all the problems inherent in paper, the SnapCheck Digital Checking Platform gives businesses, banks, and consumers collectively the opportunity to save over $50 Billion a year in costs.

Sam Ackley, GM of Payroc’s ACHeck21 division, stated: “We have worked with SnapCheck for several years, and together have brought to market a number of innovations that have provided significant savings and payments improvements for businesses across the country. We are impressed and fascinated by their technology, and see the SnapCheck Digital Checking Platform as the missing link to eliminating paper checks.”

Ken Kruszka, CEO of SnapCheck, added: “With a reach into over 40 countries, and serving over 100,000 merchants, Payroc/ACHeck21 offers a market access opportunity beyond our wildest dreams. Marrying together the SnapCheck platform with their already best-in-class payment processing technology will help springboard our mission to modernize business payments in the US and around the world. We’re excited about this new future together!”

Founded in 2015, SnapCheck has garnered a number of awards including:

– Featured startup at Money2020

– Selected as Best Payments API by API:World

– Recognized by KPMG as a Top 20 Global FinTech Startup

– Inducted into the BBVA Walk of Fame

– Chosen as a RedHerring Top100 North America Winner

– Named a Top Fintech Innovation Trend by NetGuru

For more information on the acquisition, please contact ACHeck21.

SnapCheck

Pat Roberts

415-949-1049

snapcheck.co

ContactContact

Categories

  • Banking & Financial Services